Is ACH or BDSX more profitable?

Accendra Health has a net margin of -11.41% compared to Biodesix's net margin of -26.97%. Accendra Health's return on equity of -4.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Accendra Health -11.41% -4.02% 0.70% Biodesix -26.97% -788.19% -30.33%

Is XGN or ACH more profitable?

Accendra Health has a net margin of -11.41% compared to Exagen's net margin of -26.61%. Accendra Health's return on equity of -4.02% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -26.61% -104.46% -28.93% Accendra Health -11.41% -4.02% 0.70%

Is LFMD or ACH more profitable?

LifeMD has a net margin of 0.10% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -168.23% -31.27% Accendra Health -11.41% -4.02% 0.70%

Do analysts recommend JYNT or ACH?

Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 40.19%. Given Accendra Health's higher probable upside, analysts clearly believe Accendra Health is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Joint 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Accendra Health 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is JYNT or ACH more profitable?

Joint has a net margin of 6.49% compared to Accendra Health's net margin of -11.41%. Joint's return on equity of 12.02% beat Accendra Health's return on equity. Company Net Margins Return on Equity Return on Assets Joint 6.49% 12.02% 3.47% Accendra Health -11.41% -4.02% 0.70%

Accendra Health (ACH) Competitors

$1.07 -0.01 (-0.93%)

As of 09/11/2026 03:58 PM Eastern

Compare

ACH vs. BDSX, INFU, XGN, LFMD, and JYNT

Should you buy Accendra Health stock or one of its competitors? Accendra Health's main competitors and comparable companies include Biodesix (BDSX), InfuSystem (INFU), Exagen (XGN), LifeMD (LFMD), and Joint (JYNT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Accendra Health compare to Biodesix?

Accendra Health (NYSE:ACH) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Accendra Health has a net margin of -11.41% compared to Biodesix's net margin of -26.97%. Accendra Health's return on equity of -4.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
Biodesix	-26.97%	-788.19%	-30.33%

Accendra Health has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market.

In the previous week, Biodesix had 6 more articles in the media than Accendra Health. MarketBeat recorded 6 mentions for Biodesix and 0 mentions for Accendra Health. Biodesix's average media sentiment score of 1.06 beat Accendra Health's score of 0.00 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Accendra Health	Neutral
Biodesix	Positive

Accendra Health presently has a consensus target price of $1.50, suggesting a potential upside of 40.19%. Biodesix has a consensus target price of $31.33, suggesting a potential upside of 16.18%. Given Accendra Health's higher possible upside, equities analysts plainly believe Accendra Health is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Biodesix has lower revenue, but higher earnings than Accendra Health. Biodesix is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A
Biodesix	$88.50M	3.22	-$35.26M	-$3.17	N/A

21.0% of Biodesix shares are owned by institutional investors. 2.3% of Accendra Health shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Biodesix beats Accendra Health on 10 of the 17 factors compared between the two stocks.

How does Accendra Health compare to InfuSystem?

Accendra Health (NYSE:ACH) and InfuSystem (NYSE:INFU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

InfuSystem has a net margin of 1.12% compared to Accendra Health's net margin of -11.41%. InfuSystem's return on equity of 2.78% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accendra Health	-11.41%	-4.02%	0.70%
InfuSystem	1.12%	2.78%	1.41%

71.1% of InfuSystem shares are owned by institutional investors. 2.3% of Accendra Health shares are owned by insiders. Comparatively, 10.8% of InfuSystem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Accendra Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, InfuSystem has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

InfuSystem has lower revenue, but higher earnings than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A
InfuSystem	$143.34M	1.71	$870K	$0.41	29.63

In the previous week, InfuSystem had 1 more articles in the media than Accendra Health. MarketBeat recorded 1 mentions for InfuSystem and 0 mentions for Accendra Health. InfuSystem's average media sentiment score of 1.63 beat Accendra Health's score of 0.00 indicating that InfuSystem is being referred to more favorably in the news media.

Company	Overall Sentiment
Accendra Health	Neutral
InfuSystem	Very Positive

Accendra Health currently has a consensus price target of $1.50, suggesting a potential upside of 40.19%. InfuSystem has a consensus price target of $16.67, suggesting a potential upside of 37.17%. Given Accendra Health's higher probable upside, equities research analysts clearly believe Accendra Health is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

InfuSystem beats Accendra Health on 13 of the 16 factors compared between the two stocks.

How does Accendra Health compare to Exagen?

Exagen (NASDAQ:XGN) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Accendra Health has a net margin of -11.41% compared to Exagen's net margin of -26.61%. Accendra Health's return on equity of -4.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-26.61%	-104.46%	-28.93%
Accendra Health	-11.41%	-4.02%	0.70%

In the previous week, Exagen had 5 more articles in the media than Accendra Health. MarketBeat recorded 5 mentions for Exagen and 0 mentions for Accendra Health. Exagen's average media sentiment score of 1.18 beat Accendra Health's score of 0.00 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Positive
Accendra Health	Neutral

Exagen has higher earnings, but lower revenue than Accendra Health. Exagen is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	2.56	-$19.95M	-$0.81	N/A
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

Exagen presently has a consensus price target of $9.63, suggesting a potential upside of 36.91%. Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 40.19%. Given Accendra Health's higher possible upside, analysts clearly believe Accendra Health is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

75.3% of Exagen shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 2.3% of Accendra Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Exagen has a beta of 2.1, indicating that its stock price is 110% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

Summary

Exagen beats Accendra Health on 11 of the 17 factors compared between the two stocks.

How does Accendra Health compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

LifeMD has higher earnings, but lower revenue than Accendra Health. LifeMD is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.76	$14.35M	-$0.05	N/A
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

LifeMD presently has a consensus price target of $7.57, suggesting a potential upside of 148.24%. Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 40.19%. Given LifeMD's stronger consensus rating and higher probable upside, equities research analysts clearly believe LifeMD is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

LifeMD has a net margin of 0.10% compared to Accendra Health's net margin of -11.41%. Accendra Health's return on equity of -4.02% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-168.23%	-31.27%
Accendra Health	-11.41%	-4.02%	0.70%

In the previous week, LifeMD had 5 more articles in the media than Accendra Health. MarketBeat recorded 5 mentions for LifeMD and 0 mentions for Accendra Health. LifeMD's average media sentiment score of 0.90 beat Accendra Health's score of 0.00 indicating that LifeMD is being referred to more favorably in the media.

Company	Overall Sentiment
LifeMD	Positive
Accendra Health	Neutral

LifeMD has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

35.5% of LifeMD shares are held by institutional investors. 17.2% of LifeMD shares are held by company insiders. Comparatively, 2.3% of Accendra Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

LifeMD beats Accendra Health on 12 of the 16 factors compared between the two stocks.

How does Accendra Health compare to Joint?

Joint (NASDAQ:JYNT) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Joint has a net margin of 6.49% compared to Accendra Health's net margin of -11.41%. Joint's return on equity of 12.02% beat Accendra Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	6.49%	12.02%	3.47%
Accendra Health	-11.41%	-4.02%	0.70%

In the previous week, Joint had 1 more articles in the media than Accendra Health. MarketBeat recorded 1 mentions for Joint and 0 mentions for Accendra Health. Joint's average media sentiment score of 1.81 beat Accendra Health's score of 0.00 indicating that Joint is being referred to more favorably in the media.

Company	Overall Sentiment
Joint	Very Positive
Accendra Health	Neutral

Joint has higher earnings, but lower revenue than Accendra Health. Accendra Health is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.02	$2.91M	$0.27	29.07
Accendra Health	$2.73B	0.03	-$1.10B	-$3.91	N/A

76.9% of Joint shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 2.3% of Accendra Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Joint has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Accendra Health has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Accendra Health has a consensus price target of $1.50, suggesting a potential upside of 40.19%. Given Accendra Health's higher probable upside, analysts clearly believe Accendra Health is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Accendra Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Joint beats Accendra Health on 12 of the 15 factors compared between the two stocks.

Get Accendra Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACH vs. The Competition

Export

Metric	Accendra Health	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$83.06M	$9.84B	$7.16B	$23.38B
Dividend Yield	N/A	2.61%	2.57%	3.56%
P/E Ratio	-0.27	33.53	274.94	28.72
Price / Sales	0.03	4.89	685.44	21.18
Price / Cash	0.28	125.15	76.65	34.17
Price / Book	-0.18	5.29	10.33	4.74
Net Income	-$1.10B	$313.25M	$3.50B	$1.07B
7 Day Performance	-11.93%	-1.26%	-3.32%	-2.00%
1 Month Performance	-2.73%	-1.53%	-0.53%	-3.20%
1 Year Performance	N/A	58.44%	23.51%	10.51%

Accendra Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACH Accendra Health	1.4157 of 5 stars	$1.07 -0.9%	$1.50 +40.2%	N/A	$83.06M	$2.73B	N/A	6,500	Gap Up
BDSX Biodesix	3.8007 of 5 stars	$26.20 -3.3%	$31.33 +19.6%	+259.5%	$274.64M	$88.50M	N/A	220	Positive News Analyst Upgrade
INFU InfuSystem	3.8606 of 5 stars	$12.14 -0.5%	$16.67 +37.3%	+21.6%	$245.01M	$143.34M	202.37	410	Positive News
XGN Exagen	4.3125 of 5 stars	$6.98 -4.5%	$9.63 +37.8%	-27.8%	$169.42M	$66.57M	N/A	220	News Coverage Positive News Analyst Forecast
LFMD LifeMD	2.4614 of 5 stars	$3.06 +3.6%	$7.57 +147.8%	-47.4%	$146.77M	$194.05M	N/A	230	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ACH) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accendra Health (ACH) Competitors

ACH vs. BDSX, INFU, XGN, LFMD, and JYNT

How does Accendra Health compare to Biodesix?

Summary

How does Accendra Health compare to InfuSystem?

Summary

How does Accendra Health compare to Exagen?

Summary

How does Accendra Health compare to LifeMD?

Summary

How does Accendra Health compare to Joint?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACH vs. The Competition

Accendra Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Accendra Health (ACH) Competitors

ACH vs. BDSX, INFU, XGN, LFMD, and JYNT

How does Accendra Health compare to Biodesix?

Is ACH or BDSX more profitable?

Which has more volatility and risk, ACH or BDSX?

Does the media refer more to ACH or BDSX?

Do analysts recommend ACH or BDSX?

Which has preferable valuation and earnings, ACH or BDSX?

Do institutionals and insiders hold more shares of ACH or BDSX?

Summary

How does Accendra Health compare to InfuSystem?

Is ACH or INFU more profitable?

Do institutionals & insiders hold more shares of ACH or INFU?

Which has more risk & volatility, ACH or INFU?

Which has stronger earnings & valuation, ACH or INFU?

Does the media refer more to ACH or INFU?

Do analysts recommend ACH or INFU?

Summary

How does Accendra Health compare to Exagen?

Is XGN or ACH more profitable?

Does the media favor XGN or ACH?

Which has better valuation & earnings, XGN or ACH?

Do analysts prefer XGN or ACH?

Do insiders and institutionals hold more shares of XGN or ACH?

Which has more volatility and risk, XGN or ACH?

Summary

How does Accendra Health compare to LifeMD?

Which has higher valuation and earnings, LFMD or ACH?

Do analysts rate LFMD or ACH?

Is LFMD or ACH more profitable?

Does the media favor LFMD or ACH?

Which has more volatility and risk, LFMD or ACH?

Do institutionals and insiders believe in LFMD or ACH?

Summary

How does Accendra Health compare to Joint?

Is JYNT or ACH more profitable?

Does the media favor JYNT or ACH?

Which has preferable earnings and valuation, JYNT or ACH?

Do institutionals & insiders have more ownership in JYNT or ACH?

Which has more volatility & risk, JYNT or ACH?

Do analysts recommend JYNT or ACH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACH vs. The Competition

Accendra Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools